ArticleJournal of applied clinical medical physics2026
Determining optimal conformity index values in pelvic region radiotherapy planning under ICRU 50/62, ICRU 83, and RTOG/NRG guidelines.
Article in Journal of applied clinical medical physics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
Abstract
backgroundConformity evaluation is essential for assessing radiotherapy plan quality, yet widely used indices such as the ICRU and Paddick Conformity Index do not distinguish between target underdosage and peripheral overdose. As clinical protocols differ in their target coverage definitions ICRU 50/62, ICRU 83, and RTOG/NRG direct comparisons of plan conformity across protocols remain challenging. Recently proposed metrics the Universal Conformity Index (CI) and Unconformity Indices (UCIu for underdose and UCIo for overdose) provide a decomposed, interpretable assessment of dose target relationships. However, protocol-specific optimal ranges for these indices and their clinical achievability have not been systematically established for pelvic radiotherapy. PURPOSE: To determine protocol-specific optimal (p10-p90) ranges for CI, UCIu, and UCIo across pelvic sites under ICRU 50/62, ICRU 83, and RTOG/NRG frameworks, and to verify whether these optimal values are clinically achievable using modern IMRT plans.
methodsThis study analyzed 40 anonymized pelvic cancer cases (20 prostate, 10 rectum, 10 endometrium). All cases were replanned under standardized dose prescriptions following ICRU 50/62, ICRU 83, and RTOG/NRG protocols. Two geometric configurations were evaluated: Target 1 (strict) and Target 2 (conservative). Stage 1: Using protocol-specific V95(%) definitions, theoretical optimal CI, UCIu, and UCIo bands (p10-p90) were calculated separately for each site and protocol under Target 1 and Target 2. Stage 2: All 40 cases were combined into a pooled pelvic dataset to derive region-wide optimal ranges and assess generalizability across sites. Stage 3: Clinical IMRT plans satisfying ICRU, RTOG, and QUANTEC constraints were generated for all patients, and clinical CI, UCIu, and UCIo values were compared against theoretical optimal bands. Statistical analysis included percentile bands, 95% Confidence Interval, p value, and effect size (η
resultsAcross all pelvic sites, CI values decreased progressively from ICRU 50/62 to ICRU 83 and RTOG/NRG (p < 0.001), while UCIu and UCIo increased systematically, reflecting protocol-driven differences in coverage tolerance. Margin expansion from Target 1 to Target 2 further reduced CI and increased UCIo. Pooled pelvic optimal ranges showed tight reproducibility with narrow 95% confidence intervals (± 0.006-0.016). Strong protocol effects were observed for CI (η
conclusionsThis study provides the protocol-specific and clinically achievable optimal ranges for CI, UCIu, and UCIo for pelvic radiotherapy across ICRU 50/62, ICRU 83, and RTOG/NRG frameworks. The combined theoretical, pooled, and clinical validation approach demonstrates that these decomposed conformity indices are robust, reproducible, and directly applicable to routine IMRT plan evaluation. The resulting optimal bands offer standardized benchmarks for assessing dose conformity and dose spill, improving cross-protocol comparability and supporting future development of quantitative conformity-based guidelines in radiotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.